Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial

BACKGROUND: VRC01 is an HIV-1 CD4 binding site broadly neutralizing antibody (bnAb) that is active against a broad range of HIV-1 primary isolates in vitro and protects against simian-human immunodeficiency virus (SHIV) when delivered parenterally to nonhuman primates. It has been shown to be safe a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:PLoS Med
Autores principales: Mayer, Kenneth H., Seaton, Kelly E., Huang, Yunda, Grunenberg, Nicole, Isaacs, Abby, Allen, Mary, Ledgerwood, Julie E., Frank, Ian, Sobieszczyk, Magdalena E., Baden, Lindsey R., Rodriguez, Benigno, Van Tieu, Hong, Tomaras, Georgia D., Deal, Aaron, Goodman, Derrick, Bailer, Robert T., Ferrari, Guido, Jensen, Ryan, Hural, John, Graham, Barney S., Mascola, John R., Corey, Lawrence, Montefiori, David C.
Formato: Artigo
Lenguaje:Inglês
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5685476/
https://ncbi.nlm.nih.gov/pubmed/29136037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pmed.1002435
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares